Strategic Programs Relmada Therapeutics is a clinical-stage biotech focused on oncology and CNS disorders, with NDV-01 for high-grade non-muscle invasive bladder cancer in Phase 2 and sepranolone in Phase 2b-ready studies for compulsion-related disorders, signaling potential cross-disease collaboration and expansion opportunities in urology and neuropsychiatry.

Key Hires Recent senior advisory appointments for the sepranolone program, including Dr. Michael Quirk, bring neuroscience drug discovery leadership, suggesting a priority to accelerate program milestones and outreach to venture partners and potential strategic collaborations.

Funding Momentum Significant private placement activity and planned financings (USD 160M in March 2026; prior $100M offering) indicate strong investor appetite and capacity to fund trials, enabling proactive BD discussions around co-development, licensing, or milestone-based partnerships.

Clinical Expansion Active clinical development in bladder cancer NDV-01 and CNS/psychiatric programs positions Relmada as a partner for specialty clinics, academic collaborations, and contract research organizations seeking novel mechanisms in oncology and neurodevelopmental disorders.

Operational Footprint Mid-sized team (11-50 employees) with cloud-based tech stack suggests scalable operations and potential for partnerships with CROs, biotech service integrators, and regional distributors to accelerate trials and regulatory filings.